

Text Search

10/677980

Baskar, P.
101677980

FILE 'REGISTRY' ENTERED AT 15:50:06 ON 22 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 NOV 2005 HIGHEST RN 868586-21-4
DICTIONARY FILE UPDATES: 21 NOV 2005 HIGHEST RN 868586-21-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

- key terms

L1 E GLYCOPHORIN A/CN 5
27 S GLYCOPHORIN A ?/CN
E BAEBL/CN 5

L8 E FORMAMIDE/CN 5
1 S E3

L13 8 S ("QS-21" OR "DETOX-PC" OR "MPL-SE" OR "MOGM-CSF" OR "TITE
L14 11 S (QS 21 OR DETOX-PC OR MOGM CSF OR TITERMAX G OR CRL 1005
L15 1 S DETOX PC/CN
E MOGM/CN
L16 1 S GCMAF/CN
E TITERMAX/CN 5
L17 2 S E3-4
E "B-ALETHINE"/CN 5
E "B-ALETHINE"/CN 5
L18 1 S E3
L19 19 S L13 OR L14 OR L15 OR L16 OR L17 OR L18

10/677980

L23 1 S PSC 97B/CN
E GERBU/CN
L24 4 S GERBU ?/CN
E "GM-CSF"/CN 5
L28 9 S "GM-CSF"?/CN

FILE 'HCAPLUS' ENTERED AT 15:50:06 ON 22 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Nov 2005 VOL 143 ISS 22
FILE LAST UPDATED: 21 Nov 2005 (20051121/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1 27 SEA FILE=REGISTRY ABB=ON PLU=ON GLYCOPHORIN A ?/CN
L2 12304 SEA FILE=HCAPLUS ABB=ON PLU=ON L1 OR BAEBL OR ERYTHROCYT?
BIND? OR GLYCOPHORIN(W) (A OR B OR C OR E OR HA) OR
(EBA175 OR EBA OR EBP) (S) ERYTHROCYT? OR GLYCOCONNECTIN OR
GLYCO CONNECTIN OR SIALOGLYCOPROTEIN OR SIALO(W) (GLYCOPROTE
IN OR GLYCO PROTEIN) OR SIALOGLYCO PROTEIN
L3 284 SEA FILE=HCAPLUS ABB=ON PLU=ON L2 AND (PLASMODIUM OR
P) (W) FALCIPARUM
L7 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND FORMAMIDE

L1 27 SEA FILE=REGISTRY ABB=ON PLU=ON GLYCOPHORIN A ?/CN
L2 12304 SEA FILE=HCAPLUS ABB=ON PLU=ON L1 OR BAEBL OR ERYTHROCYT?
BIND? OR GLYCOPHORIN(W) (A OR B OR C OR E OR HA) OR
(EBA175 OR EBA OR EBP) (S) ERYTHROCYT? OR GLYCOCONNECTIN OR
GLYCO CONNECTIN OR SIALOGLYCOPROTEIN OR SIALO(W) (GLYCOPROTE
IN OR GLYCO PROTEIN) OR SIALOGLYCO PROTEIN
L3 284 SEA FILE=HCAPLUS ABB=ON PLU=ON L2 AND (PLASMODIUM OR
P) (W) FALCIPARUM
L13 8 SEA FILE=REGISTRY ABB=ON PLU=ON ("QS-21" OR "DETOX-PC"
OR "MPL-SE" OR "MOGM-CSF" OR "TITERMAX-G" OR "CRL-1005" OR
GERBU OR TERAMIDE OR PSC97B OR ADJUMER OR "PG-026" OR
"GSK-1" OR GCMF OR "B-ALETHINE" OR "MPC-026" OR ADJUVAX
OR CPG ODN OR BETAPECTIN OR ALUM OR MF59)/CN
L14 11 SEA FILE=REGISTRY ABB=ON PLU=ON (QS 21 OR DETOX-PC OR
MOGM CSF OR TITERMAX G OR CRL 1005 OR PSC 97B OR ADJUMER
OR PG 026 OR GSK 1 OR B ALETHINE OR MPC 026 OR BETAPECTIN
OR ALUM OR MF 59)/CN

Searcher : Shears 571-272-2528

10/677980

L15 1 SEA FILE=REGISTRY ABB=ON PLU=ON DETOX PC/CN
L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON GCMAF/CN
L17 2 SEA FILE=REGISTRY ABB=ON PLU=ON (TITERMAX/CN OR "TITERMAX
GOLD"/CN)
L18 1 SEA FILE=REGISTRY ABB=ON PLU=ON B-ALETHINE/CN
L19 19 SEA FILE=REGISTRY ABB=ON PLU=ON L13 OR L14 OR L15 OR L16
OR L17 OR L18
L20 47043 SEA FILE=HCAPLUS ABB=ON PLU=ON L19 OR QS21 OR QS 21 OR
DETOX PC OR MPL SE OR MOGM OR TITERMAX OR CRL 1005 OR
GERBU OR TERAMIDE OR PSC97B OR ADJUMER OR (PG OR MPC) (W) (02
6 OR 26) OR GSK(W) (1 OR I) OR GCMAF OR (B OR BETA) (W) ALETHI
NE OR ADJUVAX OR CPG ODN OR BETAPECTIN OR ALUM OR MF59 OR
MF 59
L23 1 SEA FILE=REGISTRY ABB=ON PLU=ON PSC 97B/CN
L24 4 SEA FILE=REGISTRY ABB=ON PLU=ON GERBU ?/CN
L28 9 SEA FILE=REGISTRY ABB=ON PLU=ON "GM-CSF"?/CN
L29 68994 SEA FILE=HCAPLUS ABB=ON PLU=ON L20 OR L23 OR L24 OR PSC
97B OR L28 OR GMCSF OR (GM OR GRANUL?) (1W) (CSF OR COLONY
STIMUL?)
L30 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND L29

L32 4 L7 OR L30

L32 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 11 Oct 2002

ACCESSION NUMBER: 2002:777627 HCAPLUS

DOCUMENT NUMBER: 137:293522

TITLE: **Plasmodium falciparum**
erythrocyte binding protein
BAEBL for use as vaccine against malarial
Plasmodium parasite

INVENTOR(S): Mayer, Ghislaine; Miller, Louis H.

PATENT ASSIGNEE(S): The Government of the United States of America,
Represented by the Secretary, Department of Health
and Human Services, USA

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002078603	A2	20021010	WO 2002-US10071	20020329
WO 2002078603	A3	20030828		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005239730	A1	20051027	US 2003-677980	20031002
PRIORITY APPLN. INFO.:			US 2001-281130P	P 20010402

Searcher : Shears 571-272-2528

- AB The invention relates to **Plasmodium falciparum Erythrocyte Binding Protein BAEBL** for use as a vaccine.
- IT **83869-56-1, GM-CSF**
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (MoGM-CSF; **Plasmodium falciparum erythrocyte binding protein BAEBL** for use as vaccine against malarial Plasmodium parasite)
- IT **646-08-2, β -Alethine**
9051-97-2, Adjuvax 141256-04-4, QS
-21 152521-52-3, Betafectin
172889-84-8, MF59 213018-95-2,
GERBU vaccine adjuvant 263746-33-4, Adjumer
263746-52-7, Detox-PC 263746-55-0
, GSK-1 263746-77-6, PG-
026 263757-02-4, GcMAF 263757-05-7
, MPC-026 263757-16-0, MPL-
SE 467423-50-3, TERamide
467423-52-5, PSC 97B
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**Plasmodium falciparum erythrocyte binding protein BAEBL** for use as vaccine against malarial Plasmodium parasite)
- IT **106392-12-5, CRL-1005**
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**TiterMax-Gold; Plasmodium falciparum erythrocyte binding protein BAEBL** for use as vaccine against malarial Plasmodium parasite)

L32 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 31 Aug 2001

ACCESSION NUMBER: 2001:635921 HCAPLUS

DOCUMENT NUMBER: 135:200402

TITLE: Novel method for down-regulation of amyloid

INVENTOR(S): Birk, Peter; Jensen, Martin Roland; Nielsen, Klaus Gregorius

PATENT ASSIGNEE(S): M & E Biotech A/S, Den.

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062284	A2	20010830	WO 2001-DK113	20010219
WO 2001062284	A3	20011129		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,			

UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2400838	AA	20010830	CA 2001-2400838	20010219
AU 2001033620	A5	20010903	AU 2001-33620	20010219
AU 783144	B2	20050929		
BR 2001008566	A	20021119	BR 2001-8566	20010219
EP 1259251	A2	20021127	EP 2001-905632	20010219
EP 1259251	B1	20051019		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003523402	T2	20030805	JP 2001-561348	20010219
NZ 521442	A	20030926	NZ 2001-521442	20010219
EE 200200444	A	20031215	EE 2002-444	20010219
CA 2440197	AA	20020829	CA 2002-2440197	20020219
US 2002119162	A1	20020829	US 2002-80101	20020219
WO 2002066056	A2	20020829	WO 2002-DK112	20020219
WO 2002066056	A3	20030103		
WO 2002066056	C1	20040429		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1363664	A2	20031126	EP 2002-700174	20020219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529881	T2	20040930	JP 2002-565614	20020219
NZ 527720	A	20050324	NZ 2002-527720	20020219
ZA 2002004830	A	20030915	ZA 2002-4830	20020614
US 2003086938	A1	20030508	US 2002-204362	20020816
NO 2002003961	A	20020820	NO 2002-3961	20020820
US 2004191264	A1	20040930	US 2003-643103	20030818
ZA 2003006422	A	20041118	ZA 2003-6422	20030818
PRIORITY APPLN. INFO.:			DK 2000-265	A 20000221
			US 2000-186295P	P 20000301
			WO 2001-DK113	W 20010219
			US 2001-785215	A 20010220
			DK 2001-1231	A 20010820
			US 2001-337543P	P 20011022
			WO 2002-DK112	W 20020219

AB Disclosed are novel methods for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (A β). Immunization is preferably effected by administration of analogs of autologous amyloidogenic

polypeptides, said analogs being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A β which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of A β 's B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic analogs of the amyloidogenic proteins, methods for the preparation of analogs and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

IT 83869-56-1, Gmcsf

RL: BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(vaccine for down-regulation of amyloid)

L32 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 14 Apr 2000

ACCESSION NUMBER: 2000:240985 HCAPLUS

DOCUMENT NUMBER: 132:292701

TITLE: Novel methods for therapeutic vaccination

INVENTOR(S): Steinaa, Lucilla; Mouritsen, Soren; Nielsen, Klaus
Gregorious; Haaning, Jesper; Leach, Dana; Dalum, Iben; Gautam, Anand; Birk, Peter; Karlsson, Gunilla

PATENT ASSIGNEE(S): M & E Biotech A/S, Den.

SOURCE: PCT Int. Appl., 220 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000020027	A2	20000413	WO 1999-DK525	19991005
WO 2000020027	A3	20001012		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2345817	AA	20000413	CA 1999-2345817	19991005
AU 9958510	A1	20000426	AU 1999-58510	19991005
AU 751709	B2	20020822		
EP 1117421	A2	20010725	EP 1999-945967	19991005
EP 1117421	B1	20040616		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO			
TR 200100936	T2	20010821	TR 2001-200100936	19991005
JP 2002526419	T2	20020820	JP 2000-573386	19991005

10/677980

EE 200100203	A	20021015	EE 2001-203	19991005
NZ 511055	A	20031031	NZ 1999-511055	19991005
AT 269100	E	20040715	AT 1999-945967	19991005
PT 1117421	T	20041130	PT 1999-945967	19991005
ES 2222728	T3	20050201	ES 1999-945967	19991005
EP 1502602	A2	20050202	EP 2004-76709	19991005
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2001001586	A	20010531	NO 2001-1586	20010328
ZA 2001002603	A	20020930	ZA 2001-2603	20010329
HR 2001000319	A1	20020630	HR 2001-319	20010504
US 2004141958	A1	20040722	US 2003-441779	20030519
PRIORITY APPLN. INFO.:			DK 1998-1261	A 19981005
			US 1998-105011P	P 19981020
			EP 1999-945967	A3 19991005
			US 1999-413186	A1 19991005
			WO 1999-DK525	W 19991005

AB A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. prostate specific membrane antigen (PSM), Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogs of PSM, Her2 and FGF8b, as well as nucleic acid mols. encoding these analogs. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogs of weak or non-immunogenic antigens.

IT **3700-67-2 83869-56-1, GM-CSF**
141256-04-4, QS21

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(weak antigens inserted with foreign T cell epitope as vaccines)

L32 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 10 Feb 1999

ACCESSION NUMBER: 1999:85374 HCAPLUS

DOCUMENT NUMBER: 130:250895

TITLE: Model multiple antigenic and homopolymeric peptides from non-repetitive sequences of malaria merozoite proteins elicit biologically irrelevant antibodies

AUTHOR(S): Ramasamy, R.; Kanagaratnam, R.; Chandanie, P. D. F.; Kulachelvy, K.; Ramasamy, M. S.; Dharmasena, P. M.

CORPORATE SOURCE: Molecular Biology Immunology Laboratories, Division Life Sciences, Institute Fundamental Studies, Kandy, Sri Lanka

SOURCE: Biochimica et Biophysica Acta, Molecular Basis of Disease (1999), 1453(1), 115-125

Searcher : Shears 571-272-2528

CODEN: BBADEX; ISSN: 0925-4439
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Three model peptides containing B-epitopes from conserved, non-repetitive regions of the merozoite surface antigens, MSA2 and MSA1, and the **erythrocyte binding protein EBP** of **Plasmodium falciparum** were synthesized. The peptides incorporated GPG spacers and C residues at the N and C termini, and were polymerized by oxidation to form cystine bridges.

Multiple

copies of essentially the same peptide sequences were also synthesized on a branching lysyl matrix to form a tetrameric multiple antigen peptide. Rabbits were immunized with the polymerized and multiple antigen peptides, in **alum** followed by Freund's adjuvant, and the antibody responses examined by IFA and ELISA. Reproducible antibody responses were obtained against the MSA1 and EBP but not MSA2 peptides. IgG antibody levels detected by ELISA after three injections of antigen in **alum**, increased significantly after further immunization in Freund's adjuvant. IgG levels were largely maintained for at least 23 wk after the final immunization. IgM antibodies, generally detectable only after immunization in Freund's adjuvant, were absent 23 wk later. Antibody titers against the native protein on fixed parasites, assayed by IFA, were three to five orders of magnitude lower than the corresponding ELISA titers against the peptides. Antibody-dependent inhibition of **P. falciparum** growth in vitro could not be demonstrated with the immune rabbit sera. The MSA1 and EBP peptides elicited cross-reactive antibodies. The results suggest that the selected non-repetitive sequences are conformationally constrained in the native proteins and only a small proportion of the anti-peptide antibodies bind to the native proteins. The significance of the findings for the development of peptide vaccines and the use of peptides in immunoassays is discussed.

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'MEDLINE' ENTERED AT 15:50:30 ON 22 NOV 2005

FILE 'BIOSIS' ENTERED AT 15:50:30 ON 22 NOV 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:50:30 ON 22 NOV 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 15:50:30 ON 22 NOV 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CONFSCI' ENTERED AT 15:50:30 ON 22 NOV 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'SCISEARCH' ENTERED AT 15:50:30 ON 22 NOV 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'JICST-EPLUS' ENTERED AT 15:50:30 ON 22 NOV 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'JAPIO' ENTERED AT 15:50:30 ON 22 NOV 2005

10/677980

COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

L33 1 S L7
L34 10 S L30
L35 10 S L33 OR L34
L36 6 DUP REM L35 (4 DUPLICATES REMOVED)

L36 ANSWER 1 OF 6 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-092869 [08] WPIDS
DOC. NO. CPI: C2003-023133
TITLE: New vaccine against malaria **Plasmodium**
falciparum parasite comprising
Erythrocyte Binding Protein
polypeptide.
DERWENT CLASS: B04 C06 D16
INVENTOR(S): MAYER, G; MILLER, L H
PATENT ASSIGNEE(S): (USSH) US DEPT HEALTH & HUMAN SERVICES; (MAYE-I)
MAYER G; (MILL-I) MILLER L H
COUNTRY COUNT: 100
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002078603	A2	20021010	(200308)*	EN	55
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW					
MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE					
DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG					
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM					
PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ					
VN YU ZA ZM ZW					
AU 2002338238	A1	20021015	(200432)		
US 2005239730	A1	20051027	(200571)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002078603	A2	WO 2002-US10071	20020329
AU 2002338238	A1	AU 2002-338238	20020329
US 2005239730	A1 Provisional	US 2001-281130P	20010402
	Cont of	WO 2002-US10071	20020329
		US 2003-677980	20031002

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002338238	A1 Based on	WO 2002078603

PRIORITY APPLN. INFO: US 2001-281130P 20010402; US
2003-677980 20031002

AN 2003-092869 [08] WPIDS

AB WO 200278603 A UPAB: 20030204

NOVELTY - A new vaccine composition comprises a polypeptide or polynucleotide and a vehicle. The polypeptide or polynucleotide comprises an amino acid or nucleic acid sequence, respectively, that encodes a **BAEBL** polypeptide or its portion.

ACTIVITY - Protozoacide; Immunostimulant.

Searcher : Shears 571-272-2528

No biological data given.

MECHANISM OF ACTION - Vaccine.

No biological data given.

USE - The vaccine composition is useful for preparing a medicament for vaccinating a human against a malaria Plasmodium parasite (claimed).

Dwg.0/7

L36 ANSWER 2 OF 6 EMBASE COPYRIGHT (c) 2005 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002073898 EMBASE
 TITLE: A multilateral effort to develop DNA vaccines against falciparum malaria.
 AUTHOR: Kumar S.; Epstein J.E.; Richie T.L.; Nkrumah F.K.; Soisson L.; Carucci D.J.; Hoffman S.L.
 CORPORATE SOURCE: S. Kumar, Malaria Program, Naval Medical Research Center, Silver Spring, MD 20910, United States. kumars@nmrc.navy.mil
 SOURCE: Trends in Parasitology, (1 Mar 2002) Vol. 18, No. 3, pp. 129-135.
 Refs: 55
 ISSN: 1471-4922 CODEN: TPRACT
 PUBLISHER IDENT.: S 1471-4922(01)02207-3
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; General Review
 FILE SEGMENT: 004 Microbiology
 026 Immunology, Serology and Transplantation
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 20020307
 Last Updated on STN: 20020307

AB Scientists from several organizations worldwide are working together to develop a multistage, multigene DNA-based vaccine against **Plasmodium falciparum** malaria. This collaborative vaccine development effort is named Multi-Stage DNA-based Malaria Vaccine Operation. An advisory board of international experts in vaccinology, malariology and field trials provides the scientific oversight to support the operation. This article discusses the rationale for the approach, underlying concepts and the pre-clinical development process, and provides a brief outline of the plans for the clinical testing of a multistage, multiantigen malaria vaccine based on DNA plasmid immunization technology.

L36 ANSWER 3 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:8135 BIOSIS
 DOCUMENT NUMBER: PREV200100008135
 TITLE: Protection of Aotus monkeys by **Plasmodium falciparum** EBA-175 region II DNA prime-boost immunization regimen.
 AUTHOR(S): Jones, T. R. [Reprint author]; Narum, D. L.; Gozalo, A. S.; Aguiar, J.; Fuhrmann, S. R.; Liang, H.; Haynes, J. D.; Moch, J. K.; Lucas, C.; Luu, T.; Magill, A. J.; Hoffman, S. L.; Sim, B. K. L.
 CORPORATE SOURCE: Malaria Program, Naval Medical Research Center, Silver Spring, MD, USA
 SOURCE: American Journal of Tropical Medicine and Hygiene, (March, 2000) Vol. 62, No. 3 Supplement, pp. 178-179.

print.
Meeting Info.: 49th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Houston, Texas, USA. October 29-November 02, 2000. American Society of Tropical Medicine and Hygiene.
CODEN: AJTHAB. ISSN: 0002-9637.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 21 Dec 2000
Last Updated on STN: 21 Dec 2000

L36 ANSWER 4 OF 6 MEDLINE on STN DUPLICATE 1

ACCESSION NUMBER: 1999143796 MEDLINE

DOCUMENT NUMBER: PubMed ID: 9989251

TITLE: Model multiple antigenic and homopolymeric peptides from non-repetitive sequences of malaria merozoite proteins elicit biologically irrelevant antibodies.

AUTHOR: Ramasamy R; Kanagaratnam R; Chandanie P D; Kulachelvy K; Ramasamy M S; Dharmasena P M

CORPORATE SOURCE: Molecular Biology Laboratory, Institute of Fundamental Studies, Kandy, Sri Lanka.. ramasamy@slt.lk

SOURCE: Biochimica et biophysica acta, (1999 Jan 6) 1453 (1) 115-25.
Journal code: 0217513. ISSN: 0006-3002.

PUB. COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199902

ENTRY DATE: Entered STN: 19990311
Last Updated on STN: 19990311
Entered Medline: 19990225

AB Three model peptides containing B-epitopes from conserved, non-repetitive regions of the merozoite surface antigens, MSA2 and MSA1, and the **erythrocyte binding** protein **EBP** of **Plasmodium falciparum** were synthesised. The peptides incorporated GPG spacers and C residues at the N and C termini, and were polymerised by oxidation to form cystine bridges. Multiple copies of essentially the same peptide sequences were also synthesised on a branching lysyl matrix to form a tetrameric multiple antigen peptide. Rabbits were immunised with the polymerised and multiple antigen peptides, in **alum** followed by Freund's adjuvant, and the antibody responses examined by IFA and ELISA. Reproducible antibody responses were obtained against the MSA1 and EBP but not MSA2 peptides. IgG antibody levels detected by ELISA after three injections of antigen in **alum**, increased significantly after further immunisation in Freund's adjuvant. IgG levels were largely maintained for at least 23 weeks after the final immunisation. IgM antibodies, generally detectable only after immunisation in Freund's adjuvant, were absent 23 weeks later. Antibody titres against the native protein on fixed parasites, assayed by IFA, were three to five orders of magnitude lower than the corresponding ELISA titres against the peptides. Antibody-dependent inhibition of **P. falciparum** growth in vitro could not be demonstrated with the immune rabbit sera. The MSA1 and EBP peptides elicited cross-reactive antibodies. The results suggest that the selected non-repetitive sequences are conformationally constrained in the native proteins and only a small proportion of the anti-peptide

antibodies bind to the native proteins. The significance of the findings for the development of peptide vaccines and the use of peptides in immunoassays is discussed.

L36 ANSWER 5 OF 6 MEDLINE on STN DUPLICATE 2
 ACCESSION NUMBER: 97155716 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 9002371
 TITLE: Malaria vaccine.
 AUTHOR: Khurana S K; Talib V H
 CORPORATE SOURCE: Department of Laboratory Medicine, Safdarjang Hospital, New Delhi.
 SOURCE: Indian journal of pathology & microbiology, (1996 Dec) 39 (5) 433-41.
 Journal code: 7605904. ISSN: 0377-4929.
 PUB. COUNTRY: India
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199703
 ENTRY DATE: Entered STN: 19970313
 Last Updated on STN: 19970313
 Entered Medline: 19970304

AB Recently it has become evident that the same candidate antigen can be shared by several of the parasite stages, and thus the concept of a multistage vaccine is becoming more and more attractive. A TDR Task Force evaluated the promise and stage of development of some 20 existing asexual blood stage candidate antigens and prepared a strategy for their development leading to clinical testing and field trials. Amongst these are merozoite surface protein 1 (MSP-1), Serine Rich Antigen (SERA), Apical Membrane Antigen (AMA-1), and **Erythrocyte Binding Antigen (EBA)**. A field study conducted in Tanzanian children showed that the SPf66 Colombian vaccine was safe, induced antibodies, and reduced the risk of developing clinical malaria by around 30%. This study, confirmed the potential of the vaccine to confer partial protection in areas of high as well as low intensity of transmission. Pfs25 is a leading candidate antigen for a transmission blocking vaccine. It is found in the ookinete stage of the parasite in the mosquito midgut. Gramme amounts of GMP-grade material have been produced and a vaccine based on the Pfs25 antigen formulated with **alum** should have gone into phase I and II clinical trials in the USA and Africa during 1995. Because the first malaria prototype vaccine to be tried out in people on a large scale has been the polymerized synthetic peptide developed by Patarroye on the basis of the SPf66 antigen of *P. falciparum*, the results are with much interest. It is still premature to predict the effectiveness of this vaccine globally, but its development will encourage further progress in a field that has repeatedly been characterized by raised and then dashed hopes. These various vaccines are based on the classical approach to vaccination, which is to raise host immunity against the parasite so as to reduce parasite densities or to sterilize an infection. A newer approach is development of antidiarrhoeal vaccines which aim to alleviate morbidity by suppressing immunopathology in the host. Antidiarrhoeal vaccines are based on neutralizing parasite components that induce host pathology, leaving the parasite itself directly unaffected. These effects would occur when each type of the disease is considered by itself; however, synergistic effects may be expected when they are used in combination. The rationale for vaccines based on any of these stages was that immunization of various hosts with whole parasites of each of these

stages has been able to induce protection or total transmission-blocking immunity. Less significant but not to be discounted is the fact that natural malaria infections in humans have been shown to induce immunity against every one of these parasite stages against which vaccines are being developed, an exception to this are those stages that are present only in the mosquito vector with component molecules not presented to the human host, such as exclusively ookinete antigens. For several very apparent reasons a vaccine today is conceived of as subunit as opposed to showl parasite vaccines, either in the form of a recombinant product or as synthetic peptide constructs. Genes coding for several antigens of *P. falciparum* and some of *P. vivax* have been seems to be common to many *Plasmodium* antigens; this is that they contain tandem repeats of oligopeptide sequences which often code for immunodominant epitopes. Following several decades of research on malaria vaccine development, the field at a glance may present a conflicting picture, with several achievements, and some disappointments and controversies. Issues facing the development of a malaria vaccine are complex. It is not clear how far we may yet be from achieving this goal. The work of the past decades has laid an extensive foundation of relevant knowledge and technologies, and the goal it self remains as important as ever, will scientists remain committed to this objective?

L36 ANSWER 6 OF 6 EMBASE COPYRIGHT (c) 2005 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 94150771 EMBASE

DOCUMENT NUMBER: 1994150771

TITLE: Clinical trials of *Plasmodium falciparum* erythrocytic stage vaccines.

AUTHOR: Ballou W.R.

CORPORATE SOURCE: Communicable Disease/Immunol. Div., Department of Immunology, Walter Reed Army Inst. of Research, Washington, DC 20307-5100, United States

SOURCE: American Journal of Tropical Medicine and Hygiene, (1994) Vol. 50, No. 4 SUPPL., pp. 59-65.

ISSN: 0002-9637 CODEN: AJTHAB

COUNTRY: United States

DOCUMENT TYPE: Journal; Conference Article

FILE SEGMENT: 004 Microbiology

017 Public Health, Social Medicine and Epidemiology

026 Immunology, Serology and Transplantation

037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 940622

Last Updated on STN: 940622

AB Efficacy trials for malaria blood-stage vaccines are currently underway in several field sites. Numerous issues surround the design and execution of such trials, and there are many opportunities for failure that have little to do with the vaccines per se. This review highlights some of the key issues to be considered by investigators designing such trials, including those that are unique to trials for erythrocytic stage vaccines.

FILE 'USPATFULL' ENTERED AT 15:58:53 ON 22 NOV 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 22 Nov 2005 (20051122/PD)

FILE LAST UPDATED: 22 Nov 2005 (20051122/ED)

HIGHEST GRANTED PATENT NUMBER: US6968571
 HIGHEST APPLICATION PUBLICATION NUMBER: US2005257307
 CA INDEXING IS CURRENT THROUGH 22 Nov 2005 (20051122/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 22 Nov 2005 (20051122/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2005

```
>>> USPAT2 is now available.  USPATFULL contains full text of the  <<<
>>> original, i.e., the earliest published granted patents or  <<<
>>> applications.  USPAT2 contains full text of the latest US  <<<
>>> publications, starting in 2001, for the inventions covered in  <<<
>>> USPATFULL.  A USPATFULL record contains not only the original  <<<
>>> published document but also a list of any subsequent  <<<
>>> publications.  The publication number, patent kind code, and  <<<
>>> publication date for all the US publications for an invention  <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.  <<<

>>> USPATFULL and USPAT2 can be accessed and searched together  <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to  <<<
>>> enter this cluster.  <<<
>>> Use USPATALL when searching terms such as patent assignees,  <<<
>>> classifications, or claims, that may potentially change from  <<<
>>> the earliest to the latest publication.  <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L1          27 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLYCOPHORIN A ?/CN
L2          12304 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 OR BAEBL OR ERYTHROCYT?
              BIND? OR GLYCOPHORIN(W) (A OR B OR C OR E OR HA) OR
              (EBA175 OR EBA OR EBP) (S) ERYTHROCYT? OR GLYCOCONNECTIN OR
              GLYCO CONNECTIN OR SIALOGLYCOPROTEIN OR SIALO(W) (GLYCOPROTE
              IN OR GLYCO PROTEIN) OR SIALOGLYCO PROTEIN
L3          284 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2 AND (PLASMODIUM OR
              P) (W) FALCIPARUM
L8          1 SEA FILE=REGISTRY ABB=ON  PLU=ON  FORMAMIDE/CN
L9          23155 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L8 OR FORMAMIDE OR
              FORMIMIDIC OR METHANAMIDE OR NSC 748 OR NSC748
L13         8 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("QS-21" OR "DETOX-PC"
              OR "MPL-SE" OR "MOGM-CSF" OR "TITERMAX-G" OR "CRL-1005" OR
              GERBU OR TERAMIDE OR PSC97B OR ADJUMER OR "PG-026" OR
              "GSK-1" OR GCMAF OR "B-ALETHINE" OR "MPC-026" OR ADJUVAX
              OR CPG ODN OR BETAPECTIN OR ALUM OR MF59)/CN
L14         11 SEA FILE=REGISTRY ABB=ON  PLU=ON  (QS 21 OR DETOX-PC OR
              MOGM CSF OR TITERMAX G OR CRL 1005 OR PSC 97B OR ADJUMER
              OR PG 026 OR GSK 1 OR B ALETHINE OR MPC 026 OR BETAPECTIN
              OR ALUM OR MF 59)/CN
L15         1 SEA FILE=REGISTRY ABB=ON  PLU=ON  DETOX PC/CN
L16         1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GCMAF/CN
L17         2 SEA FILE=REGISTRY ABB=ON  PLU=ON  (TITERMAX/CN OR "TITERMAX
              GOLD"/CN)
L18         1 SEA FILE=REGISTRY ABB=ON  PLU=ON  B-ALETHINE/CN
L19         19 SEA FILE=REGISTRY ABB=ON  PLU=ON  L13 OR L14 OR L15 OR L16
              OR L17 OR L18
L20         47043 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L19 OR QS21 OR QS 21 OR
              DETOX PC OR MPL SE OR MOGM OR TITERMAX OR CRL 1005 OR
```

10/677980

GERBU OR TERAMIDE OR PSC97B OR ADJUMER OR (PG OR MPC) (W) (02
6 OR 26) OR GSK(W) (1 OR I) OR GCMAF OR (B OR BETA) (W) ALETHI
NE OR ADJUVAX OR CPG ODN OR BETAFFECTIN OR ALUM OR MF59 OR
MF 59

L23 1 SEA FILE=REGISTRY ABB=ON PLU=ON PSC 97B/CN
L24 4 SEA FILE=REGISTRY ABB=ON PLU=ON GERBU ?/CN
L28 9 SEA FILE=REGISTRY ABB=ON PLU=ON "GM-CSF"?/CN
L29 68994 SEA FILE=HCAPLUS ABB=ON PLU=ON L20 OR L23 OR L24 OR PSC
97B OR L28 OR GMCFSF OR (GM OR GRANUL?) (1W) (CSF OR COLONY
STIMUL?)
L37 59 SEA FILE=USPATFULL ABB=ON PLU=ON L3 AND L29
L38 15 SEA FILE=USPATFULL ABB=ON PLU=ON L37 AND (L9 OR FORMAMIDE
)

L38 ANSWER 1 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2005:275167 USPATFULL
TITLE: **Plasmodium falciparum**
erythrocyte binding protein
baebl for use as a vaccine
INVENTOR(S): Mayer, Ghislaine, Gaithersburg, MD, UNITED STATES
Miller, Louis H., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239730	A1	20051027
APPLICATION INFO.:	US 2003-677980	A1	20031002 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2002-US10071, filed on 29 Mar 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-281130P	20010402 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1806	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention relates to Plasmodium falciparum Erythrocyte Binding Protein BAEBL for use as a vaccine.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 2 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2005:274547 USPATFULL
TITLE: Flea head, nerve cord, hindgut and malpighian
tubule nucleic acid molecules, proteins and uses
thereof
INVENTOR(S): Brandt, Kevin S., Windsor, CO, UNITED STATES
Gaines, Patrick J., Fort Collins, CO, UNITED STATES
Stinchcomb, Dan T., Fort Collins, CO, UNITED STATES
Wisnewski, Nancy, Fort Collins, CO, UNITED STATES
PATENT ASSIGNEE(S): Heska Corporation (U.S. corporation)

	NUMBER	KIND	DATE
Searcher	:	Shears	571-272-2528

10/677980

PATENT INFORMATION: US 2005239103 A1 20051027
APPLICATION INFO.: US 2004-978245 A1 20041029 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-991936, filed on
21 Nov 2001, PENDING Division of Ser. No. US
2000-543668, filed on 7 Apr 2000, ABANDONED

NUMBER DATE

PRIORITY INFORMATION: US 1999-128704P 19990409 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HESKA CORPORATION, INTELLECTUAL PROPERTY DEPT.,
3760 ROCKY MOUNTAIN AVE, LOVELAND, CO, 80538, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 7785

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to flea head, nerve cord, hindgut and Malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut and Malpighian tubule proteins; and to compounds that inhibit flea head, nerve cord, hindgut and Malpighian tubule protein activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, nucleic acid molecules, or protective compounds derived from proteins of the present invention as well as the use of such therapeutic compositions to protect animals from flea infestation. Also included in the present invention is the use of flea head, nerve cord, hindgut and Malpighian tubule proteins to derive inhibitory compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 3 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2005:240602 USPATFULL
TITLE: 89 human secreted proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Baker, Kevin P., Darnestown, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
Choi, Gil H., Rockville, MD, UNITED STATES
Fiscella, Michele, Bethesda, MD, UNITED STATES
Komatsoulis, George A., Silver Spring, MD, UNITED STATES
Moore, Paul A., North Bethesda, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
Wei, Ping, Agoura Hills, CA, UNITED STATES
Duan, D. Roxanne, Bethesda, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2005208602 A1 20050922
APPLICATION INFO.: US 2004-773236 A1 20040209 (10)

Searcher : Shears 571-272-2528

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2002-US25107, filed on 8 Aug 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US33985, filed on 24 Oct 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US35606, filed on 6 Nov 2002, PENDING Continuation-in-part of Ser. No. WO 2003-US4819, filed on 20 Feb 2003, PENDING Continuation-in-part of Ser. No. WO 2003-US4818, filed on 20 Feb 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-311085P	20010810 (60)
	US 2001-325209P	20010928 (60)
	US 2001-330629P	20011026 (60)
	US 2001-331046P	20011107 (60)
	US 2002-358554P	20020222 (60)
	US 2002-358714P	20020225 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	27921	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 4 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2005:152003 USPATFULL
 TITLE: Gene expression during meningococcus adhesion
 INVENTOR(S): Grandi, Guido, Milan, ITALY
 PATENT ASSIGNEE(S): Chiron SRL, Siena, ITALY, 1-53100 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005130917	A1	20050616
APPLICATION INFO.:	US 2003-481456	A1	20020619 (10)
	WO 2002-IB3072		20020619
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US		

NUMBER OF CLAIMS: 31
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 7 Drawing Page(s)
 LINE COUNT: 4001

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The first step in human meningococcal infection involves adhesion to the epithelial cells of the nasopharynx tract. The invention provides various methods and compounds for preventing the attachment of Neisserial cells to epithelial cells and is based on the identification of 347 meningococcal genes which play a role in the adhesion process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 5 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:315125 USPATFULL
 TITLE: Methods and reagents for regulation of cellular responses in biological systems
 INVENTOR(S): Kiessling, Laura L., Madison, WI, UNITED STATES
 Griffith, Byron R., Madison, WI, UNITED STATES
 Gestwicki, Jason E., Mountain View, CA, UNITED STATES
 Strong, Laura, Stoughton, WI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004248801	A1	20041209
APPLICATION INFO.:	US 2004-806056	A1	20040322 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-815296, filed on 21 Mar 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-456778P	20030321 (60)
	US 2000-191014P	20000321 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GREENLEE WINNER AND SULLIVAN P C, 5370 MANHATTAN CIRCLE, SUITE 201, BOULDER, CO, 80303	
NUMBER OF CLAIMS:	127	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Page(s)	
LINE COUNT:	4275	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides multivalent ligands which carry or display at least one recognition element (RE), and preferably a plurality of recognition elements, for binding directly or indirectly to cells or other biological particles or more generally by binding to any biological molecule. The multivalent ligands provided can most generally function for binding or targeting to any biological particle or molecule and particularly to targeting of cells or cell types or viruses, for cell aggregation and generally for macromolecular assembly of biological macromolecules. The multivalent ligands of this invention are generally applicable for creating scaffolds (assemblies) of chemical or biological species, including without limitation, antigens, epitopes, ligand binding groups, ligands for cell receptors (cell surface receptors, transmembrane receptors and cytoplasmic receptors), and various macromolecules (nucleic acids, carbohydrates, saccharides, proteins,

peptides, etc.). In these scaffolds, the number, spacing, relative positioning and relative orientation of recognition elements can be controlled. Multivalent ligands of this invention can carry or display at least one signal recognition element (SRE), and preferably a plurality of signal recognition elements, and modulate biological responses in biological systems. Multivalent ligands of this invention can carry or display at least one binding recognition element (BRE), and preferably a plurality of binding recognition elements, optionally in combination with one or more SRE, and modulate biological responses in biological systems. The invention also relates to methods for aggregating biological particles and macromolecules and for modulating biological response employing the multivalent ligands provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 6 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:151408 USPATFULL

TITLE: Molecules for diagnostics and therapeutics

INVENTOR(S): Panzer, Scott R, Sunnyvale, CA, UNITED STATES
 Lincoln, Stephen E, Potomac, MD, UNITED STATES
 Altus, Christina M, Campbell, CA, UNITED STATES
 Dufour, Gerard E, Castro Valley, CA, UNITED STATES
 Jackson, Jennifer L, Santa Cruz, CA, UNITED STATES
 Jones, Anissa L, San Jose, CA, UNITED STATES
 Dam, Tam C, San Jose, CA, UNITED STATES
 Liu, Tommy, Daly City, CA, UNITED STATES
 Harris, Bernard, Sunnyvale, CA, UNITED STATES
 Flores, Vincent Z, Union City, CA, UNITED STATES
 Daffo, Abel, San Jose, CA, UNITED STATES
 Marwaha, Rakesh, Burnaby, CANADA
 Chen, Alice J, San Jose, CA, UNITED STATES
 Chang, Simon C, Sunnyvale, CA, UNITED STATES
 Gerstin, Edward H, JR., San Jose, CA, UNITED STATES
 Peralta, Careyna H, Santa Clara, CA, UNITED STATES
 David, Marie H, Daly City, CA, UNITED STATES
 Lewis, Samantha A, San Leandro, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004115629	A1	20040617
APPLICATION INFO.:	US 2003-250889	A1	20030709 (10)
	WO 2002-US1009		20020109
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	INCYTE CORPORATION, 3160 PORTER DRIVE, PALO ALTO, CA, 94304		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
LINE COUNT:	16703		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides purified human polynucleotides for diagnostics and therapeutics (dithp). Also encompassed are the polypeptides (DITHP) encoded by dithp. The invention also provides for the use of dithp, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing dithp for the expression of DITHP. The invention additionally provides for the use of isolated and purified DITHP to induce antibodies and to screen libraries of

10/677980

compounds and the use of anti-DITHP antibodies in diagnostic assays.
Also provided are microarrays containing dithp and methods of use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 7 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:144630 USPATFULL
TITLE: Nucleic acid vectors
INVENTOR(S): Punnonen, Juha, Belmont, CA, UNITED STATES
Apt, Doris, Sunnyvale, CA, UNITED STATES
Whalen, Robert G., Foster City, CA, UNITED STATES
PATENT ASSIGNEE(S): Maxygen, Inc., a Delaware corporation, Redwood
City, CA, UNITED STATES, 94063 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004110295	A1	20040610
APPLICATION INFO.:	US 2003-446629	A1	20030528 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-384002P	20020528 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063	
NUMBER OF CLAIMS:	78	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	6550	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to nucleic acid vectors useful for expression
and production of polypeptides, compositions comprising vectors, and
methods for the production and use of vectors and polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 8 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:78909 USPATFULL
TITLE: Non-stochastic generation of genetic vaccines and
enzymes
INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, United States
PATENT ASSIGNEE(S): Diversa Corporation, San Diego, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6713279	B1	20040330
APPLICATION INFO.:	US 2000-498557		20000204 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-495052, filed on 31 Jan 2000, now patented, Pat. No. US 6479253 Continuation-in-part of Ser. No. US 1999-332835, filed on 14 Jun 1999, now patented, Pat. No. US 6537776 Continuation-in-part of Ser. No. US 1999-276860, filed on 26 Mar 1999, now patented, Pat. No. US 6352842 Continuation-in-part of Ser. No. US 1999-267118, filed on 9 Mar 1999, now patented, Pat. No. US 6238884 Continuation-in-part of Ser. No. US 1999-246178,		

Searcher : Shears 571-272-2528

filed on 4 Feb 1999, now patented, Pat. No. US 6171820 Continuation-in-part of Ser. No. US 1998-185373, filed on 3 Nov 1998, now patented, Pat. No. US 6335179 Continuation of Ser. No. US 1996-760489, filed on 5 Dec 1996, now patented, Pat. No. US 5830696 Continuation-in-part of Ser. No. US 1997-962504, filed on 31 Oct 1997 Continuation-in-part of Ser. No. US 1996-677112, filed on 9 Jul 1996, now patented, Pat. No. US 5965408 Continuation-in-part of Ser. No. US 1996-651568, filed on 22 May 1996, now patented, Pat. No. US 5939250

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-8311P	19951207 (60)
	US 1995-8316P	19951207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Park, Hankyel T.	
LEGAL REPRESENTATIVE:	Love, Jane M., Butler, James E.	
NUMBER OF CLAIMS:	105	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	73 Drawing Figure(s); 64 Drawing Page(s)	
LINE COUNT:	19098	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by use of non-stochastic methods of directed evolution (DirectEvolution.TM.). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis.TM.) and non-stochastic polynucleotide reassembly (GeneReassembly.TM.). Through use of the claimed methods, genetic vaccines, enzymes, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like. This invention provides methods of obtaining novel enzymes that have optimized physical &/or biological properties. Furthermore, this invention provides methods of obtaining a variety of novel biologically active molecules, in the fields of antibiotics, pharmacotherapeutics, and transgenic traits.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 9 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:63735 USPATFULL
 TITLE: Molecules for diagnostics and therapeutics
 INVENTOR(S): Panzer, Scott R., Sunnyvale, CA, UNITED STATES
 Spiro, Peter A., Palo Alto, CA, UNITED STATES
 Banville, Steven C., Palo Alto, CA, UNITED STATES
 Shah, Purvi, San Jose, CA, UNITED STATES
 Chalup, Michael S., Sunnyvale, CA, UNITED STATES
 Chang, Simon C, Mountain View, CA, UNITED STATES
 Chen, Alice J., San Jose, CA, UNITED STATES
 D'Sa, Steven A., East Palo, CA, UNITED STATES
 Amshey, Stefan, San Francisco, CA, UNITED STATES
 Dahl, Christopher E., Fremont, CA, UNITED STATES

10/677980

Dam, Tam C., San Jose, CA, UNITED STATES
Daniels, Susan E., Palo Alto, CA, UNITED STATES
Dufour, Gerard E., Castro Valley, CA, UNITED STATES
Flores, Vincent, Union City, CA, UNITED STATES
Fong, Willy T., San Francisco, CA, UNITED STATES
Greenawalt, Lila B., San Jose, CA, UNITED STATES
Jackson, Jennifer L., Mountain View, CA, UNITED STATES
Jones, Anissa L., San Jose, CA, UNITED STATES
Liu, Tommy F., Daly City, CA, UNITED STATES
Lincoln, Ann M. Roseberry, Redwood City, CA, UNITED STATES
Rosen, Bruce H., Menlo Park, CA, UNITED STATES
Russo, Frank D., Rossette Court Sunnyvale, CA, UNITED STATES
Stockdreher, Theresa K., Sunnyvale, CA, UNITED STATES
Daffo, Abel, San Jose, CA, UNITED STATES
Wright, Rachel J., Mountain View, CA, UNITED STATES
Yap, Pierre E., Lafayette, CA, UNITED STATES
Yu, Jimmy Y., Fremont, CA, UNITED STATES
Bradley, Diana L., Soquel, CA, UNITED STATES
Bratcher, Shawn R., Mountain View, CA, UNITED STATES
Chen, Wensheng, Mountain View, CA, UNITED STATES
Cohen, Howard J., Palo Alto, CA, UNITED STATES
Hodgson, David M., Ann Arbor, MI, UNITED STATES
Lincoln, Stephen E., Redwood City, CA, UNITED STATES
Jackson, Stuart E., Mountain View, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004048253	A1	20040311
APPLICATION INFO.:	US 2003-220120	A1	20030605 (10)
	WO 2001-US6059		20010221
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Incyte Genomics Inc, Legal Department, 3160 Porter Drive, Palo Alto, CA, 94304		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
LINE COUNT:	17872		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides purified human polynucleotides for diagnostics and therapeutics (dithp). Also encompassed are the polypeptides (DITHP) encoded by dithp. The invention also provides for the use of dithp, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing dithp for the expression of DITHP. The invention additionally provides for the use of isolated and purified DITHP to induce antibodies and to screen libraries of compounds and the use of anti-DITHP antibodies in diagnostic assays. Also provided are microarrays containing dithp and methods of use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 10 OF 15 USPATFULL on STN

Searcher : Shears 571-272-2528

10/677980

ACCESSION NUMBER: 2004:18785 USPATFULL
TITLE: Molecules for diagnostics and therapeutics
INVENTOR(S): Hodgson, David M., Ann Arbor, MI, UNITED STATES
Lincoln, Stephen E., Potomac, MD, UNITED STATES
Russo, Frank D., Sunnyvale, CA, UNITED STATES
Albany, Peter A., Berkeley, CA, UNITED STATES
Banville, Steve C., Sunnyvale, CA, UNITED STATES
Bratcher, Shawn R., Mountain View, CA, UNITED STATES
Dufour, Gerard E., Castro Valley, CA, UNITED STATES
Cohen, Howard J., Palo Alto, CA, UNITED STATES
Rosen, Bruce H., Menlo Park, CA, UNITED STATES
Chalup, Michael S., Livingston, TX, UNITED STATES
Jackson, Jennifer L., Santa Cruz, CA, UNITED STATES
Jones, Anissa L., San Jose, CA, UNITED STATES
Yu, Jimmy Y., Fremont, CA, UNITED STATES
Greenawalt, Lila B., San Jose, CA, UNITED STATES
Panzer, Scott R., Sunnyvale, CA, UNITED STATES
Roseberry Lincoln, Ann M., Potomac, MD, UNITED STATES
Wright, Rachel J., Merivale, NEW ZEALAND
PATENT ASSIGNEE(S): Daniels, Susan E., Mountain View, CA, UNITED STATES
Incyte Corporation, Palo Alto, CA, UNITED STATES
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014087	A1	20040122
APPLICATION INFO.:	US 2003-378029	A1	20030228 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-980285, filed on 30 Nov 2001, PENDING A 371 of International Ser. No. WO 2000-US15404, filed on 31 May 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-147500P	19990805 (60)
	US 1999-147542P	19990805 (60)
	US 1999-147541P	19990805 (60)
	US 1999-147824P	19990805 (60)
	US 1999-147547P	19990805 (60)
	US 1999-147530P	19990805 (60)
	US 1999-147536P	19990805 (60)
	US 1999-147520P	19990805 (60)
	US 1999-147527P	19990805 (60)
	US 1999-147549P	19990805 (60)
	US 1999-147377P	19990804 (60)
	US 1999-147436P	19990804 (60)
	US 1999-137411P	19990603 (60)
	US 1999-137396P	19990603 (60)
	US 1999-137417P	19990603 (60)
	US 1999-137337P	19990603 (60)
	US 1999-137173P	19990602 (60)
	US 1999-137114P	19990602 (60)
	US 1999-137259P	19990602 (60)
	US 1999-137113P	19990602 (60)
	US 1999-137260P	19990602 (60)
	US 1999-137258P	19990602 (60)
	US 1999-137109P	19990602 (60)

Searcher : Shears 571-272-2528

10/677980

US 1999-137161P 19990601 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: INCYTE CORPORATION (formerly known as Incyte,
Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA,
94304
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 14819

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides purified human polynucleotides for
diagnostics and therapeutics (dithp). Also encompassed are the
polypeptides (DITHP) encoded by dithp. The invention also provides
for the use of dithp, or complements, oligonucleotides, or fragments
thereof in diagnostic assays. The invention further provides for
vectors and host cells containing dithp for the expression of DITHP.
The invention additionally provides for the use of isolated and
purified DITHP to induce antibodies and to screen libraries of
compounds and the use of anti-DITHP antibodies in diagnostic assays.
Also provided are microarrays containing dithp and methods of use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 11 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:312155 USPATFULL

TITLE: Novel antigen binding molecules for therapeutic,
diagnostic, prophylactic, enzymatic, industrial,
and agricultural applications, and methods for
generating and screening thereof

INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, UNITED STATES
PATENT ASSIGNEE(S): Diversa Corporation, San Diego, CA, UNITED STATES,
92121 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219752	A1	20031127
APPLICATION INFO.:	US 2002-151469	A1	20020517 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-535754, filed on 27 Mar 2000, GRANTED, Pat. No. US 6361974 Continuation-in-part of Ser. No. US 2000-522289, filed on 9 Mar 2000, GRANTED, Pat. No. US 6358709 Continuation-in-part of Ser. No. US 2000-498557, filed on 4 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-495052, filed on 31 Jan 2000, GRANTED, Pat. No. US 6479258 Continuation-in-part of Ser. No. US 1999-276860, filed on 26 Mar 1999, GRANTED, Pat. No. US 6352842 Continuation-in-part of Ser. No. US 1999-267118, filed on 9 Mar 1999, GRANTED, Pat. No. US 6238884 Continuation-in-part of Ser. No. US 1999-246178, filed on 4 Feb 1999, GRANTED, Pat. No. US 6171820 Continuation of Ser. No. US 1998-185373, filed on 3 Nov 1998, GRANTED, Pat. No. US 6335179 Continuation of Ser. No. US 1996-760489, filed on 5 Dec 1996, GRANTED, Pat. No. US 5830696 Continuation-in-part of Ser. No. US 1996-677112, filed on 9 Jul 1996, GRANTED, Pat. No. US 5965408 Continuation-in-part of Ser. No. WO 2000-US16838, filed on 14 Jun 2000, PENDING Continuation-in-part of Ser. No. WO 2000-US8245,		

Searcher : Shears 571-272-2528

10/677980

filed on 27 Mar 2000, PENDING Continuation-in-part of Ser. No. WO 2000-US6497, filed on 9 Mar 2000, PENDING Continuation-in-part of Ser. No. US 2000-594459, filed on 14 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-332835, filed on 14 Jun 1999, GRANTED, Pat. No. US 6537776 Continuation-in-part of Ser. No. WO 2000-US3086, filed on 4 Feb 2000, PENDING Continuation-in-part of Ser. No. US 2001-756459, filed on 8 Jan 2001, PENDING Continuation of Ser. No. US 1999-246178, filed on 4 Feb 1999, GRANTED, Pat. No. US 6171820 Continuation of Ser. No. US 1998-185373, filed on 3 Nov 1998, GRANTED, Pat. No. US 6335179 Continuation-in-part of Ser. No. US 1996-760489, filed on 5 Dec 1996, GRANTED, Pat. No. US 5830696 Continuation-in-part of Ser. No. US 1999-376727, filed on 17 Aug 1999, GRANTED, Pat. No. US 6440668 Continuation of Ser. No. US 1996-677112, filed on 9 Jul 1996, GRANTED, Pat. No. US 5965408 Continuation-in-part of Ser. No. WO 1998-US22596, filed on 23 Oct 1998, PENDING Continuation-in-part of Ser. No. US 1999-214645, filed on 27 Sep 1999, PENDING A 371 of International Ser. No. WO 1997-US12239, filed on 9 Jul 1997, PENDING Continuation-in-part of Ser. No. US 2001-790321, filed on 21 Feb 2001, PENDING Division of Ser. No. US 2000-687219, filed on 12 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-636778, filed on 11 Aug 2000, PENDING Continuation of Ser. No. US 1998-98206, filed on 16 Jun 1998, GRANTED, Pat. No. US 6174673 Continuation-in-part of Ser. No. US 2001-876276, filed on 7 Jun 2001, GRANTED, Pat. No. US 6468724 Continuation-in-part of Ser. No. US 2001-761559, filed on 16 Jan 2001, PENDING Division of Ser. No. US 1998-98206, filed on 16 Jun 1998, GRANTED, Pat. No. US 6174673 Continuation-in-part of Ser. No. US 1997-876276, filed on 16 Jun 1997, PENDING Continuation-in-part of Ser. No. US 2001-848185, filed on 3 May 2001, PENDING Division of Ser. No. US 2000-636778, filed on 11 Aug 2000, PENDING Continuation of Ser. No. US 1998-98206, filed on 16 Jun 1998, GRANTED, Pat. No. US 6174673 Continuation-in-part of Ser. No. US 1997-876276, filed on 16 Jun 1997, PENDING Continuation-in-part of Ser. No. US 2000-738871, filed on 15 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-685432, filed on 10 Oct 2000, PENDING Continuation-in-part of Ser. No. US 1999-444112, filed on 22 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1998-98206, filed on 16 Jun 1998, GRANTED, Pat. No. US 6174673 Continuation-in-part of Ser. No. US 1997-876276, filed on 16 Jun 1997, PENDING Continuation-in-part of Ser. No. WO 2000-US32208, filed on 22 Nov 2000, PENDING Continuation-in-part of Ser. No. WO 1998-US12674, filed on 16 Jun 1998, PENDING

NUMBER

DATE

Searcher : Shears 571-272-2528

10/677980

PRIORITY INFORMATION: US 2001-300381P 20010517 (60)
US 2001-300907P 20010625 (60)
US 1995-8311P 19951207 (60)
US 1995-8316P 19951207 (60)
US 1995-8311P 19951207 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON, PC, 4350 LA JOLLA VILLAGE DRIVE,
SUITE 500, SAN DIEGO, CA, 92122
NUMBER OF CLAIMS: 102
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 95 Drawing Page(s)
LINE COUNT: 23775
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to methods for generating sets, or libraries, of nucleic acids encoding antigen-binding sites, such as antibodies, antibody domains or other fragments, including single and double stranded antibodies, major histocompatibility complex (MHC) molecules, T cell receptors (TCRs), and the like. This invention provides methods for generating variant antigen binding sites, e.g., antibodies and specific domains or fragments of antibodies (e.g., Fab or Fc domains), by altering template nucleic acids including by saturation mutagenesis, synthetic ligation reassembly, or a combination thereof. In one aspect, invention provides methods for generating all human or humanized antibodies and evolving them to achieve optimized properties related to stability, duration, expression, production, enzymatic activity, affinity, avidity, localization, and other immunological properties. Polypeptides generated by these methods can be analyzed using a novel capillary array platform, which provides unprecedented ultra-high throughput screening.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 12 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2003:294272 USPATFULL
TITLE: Non-stochastic generation of genetic vaccines
INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207287	A1	20031106
APPLICATION INFO.:	US 2002-223507	A1	20020819 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-495052, filed on 31 Jan 2000, GRANTED, Pat. No. US 6479258		
	Continuation-in-part of Ser. No. US 1999-276860, filed on 26 Mar 1999, GRANTED, Pat. No. US 6352842		
	Continuation-in-part of Ser. No. US 1999-267118, filed on 9 Mar 1999, GRANTED, Pat. No. US 6238884		
	Continuation-in-part of Ser. No. US 1999-246178, filed on 4 Feb 1999, GRANTED, Pat. No. US 6171820		
	Continuation-in-part of Ser. No. US 1998-185373, filed on 3 Nov 1998, GRANTED, Pat. No. US 6335179		
	Continuation of Ser. No. US 1996-760489, filed on 5 Dec 1996, GRANTED, Pat. No. US 5830696		
	Continuation-in-part of Ser. No. US 1996-677112, filed on 9 Jul 1996, GRANTED, Pat. No. US 5965408		

NUMBER DATE

Searcher : Shears 571-272-2528

PRIORITY INFORMATION: US 1995-8311P 19951207 (60)
 US 1995-8316P 19951207 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HALE AND DORR LLP, 300 PARK AVENUE, NEW YORK, NY,
 10022

NUMBER OF CLAIMS: 69

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 61 Drawing Page(s)

LINE COUNT: 20997

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods of obtaining vaccines by use of non-stochastic methods of directed evolution (DirectEvolution.TM.). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis.TM.) and non-stochastic polynucleotide reassembly (GeneReassembly.TM.). Through use of the claimed methods, vectors can be obtained which exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 13 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:250508 USPATFULL

TITLE: Heterologous fusion protein constructs comprising a Leishmania antigen

INVENTOR(S): Skeiky, Yasir, Bellevue, WA, UNITED STATES
 Brannon, Mark, Seattle, WA, UNITED STATES
 Guderian, Jeffrey, Lynwood, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175294	A1	20030918
APPLICATION INFO.:	US 2002-98732	A1	20020313 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-275837P	20010313 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	82	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	6952	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a recombinant nucleic acid molecule encoding a fusion polypeptide, wherein the recombinant nucleic acid comprises a heterologous polynucleotide sequence encoding an antigen or an antigenic fragment, and a Leishmania polynucleotide sequence encoding a polypeptide or fragment thereof, wherein the Leishmania

10/677980

polynucleotide is selected from the group consisting of TSA polynucleotide, LeIF polynucleotide, M15 polynucleotide, and 6H polynucleotide. The invention also provides an expression cassette comprising the recombinant nucleic acid molecule, host cells comprising the expression cassette, compositions, fusion polypeptides, and methods of their use in diagnosis or in generating a protective immune response in hosts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 14 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:106914 USPATFULL

TITLE: Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof

INVENTOR(S): Brandt, Kevin S., Windsor, CO, UNITED STATES
Gaines, Patrick J., Fort Collins, CO, UNITED STATES
Stinchcomb, Dan T., Fort Collins, CO, UNITED STATES
Wisnewski, Nancy, Fort Collins, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073827	A1	20030417
APPLICATION INFO.:	US 2001-991936	A1	20011121 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-543668, filed on 7 Apr 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-128704P	19990409 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HESKA CORPORATION, INTELLECTUAL PROPERTY DEPT., 1613 PROSPECT PARKWAY, FORT COLLINS, CO, 80525	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7791	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to flea head, nerve cord, hindgut and Malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut and Malpighian tubule proteins; and to compounds that inhibit flea head, nerve cord, hindgut and Malpighian tubule protein activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, nucleic acid molecules, or protective compounds derived from proteins of the present invention as well as the use of such therapeutic compositions to protect animals from flea infestation. Also included in the present invention is the use of flea head, nerve cord, hindgut and Malpighian tubule proteins to derive inhibitory compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L38 ANSWER 15 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:297432 USPATFULL

Searcher : Shears 571-272-2528

10/677980

TITLE: Non-stochastic generation of genetic vaccines
INVENTOR(S): Short, Jay M., Rancho Santa Fe, CA, United States
PATENT ASSIGNEE(S): Diversa Corporation, San Diego, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6479258	B1	20021112
APPLICATION INFO.:	US 2000-495052		20000131 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-276860, filed on 26 Mar 1999 Continuation-in-part of Ser. No. US 1999-246178, filed on 4 Feb 1999, now patented, Pat. No. US 6171820 Continuation-in-part of Ser. No. US 1998-185373, filed on 3 Nov 1998 Continuation-in-part of Ser. No. US 1996-760489, filed on 5 Dec 1996, now patented, Pat. No. US 5830696		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-8311P	19951207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Park, Hankyel T.	
LEGAL REPRESENTATIVE:	Gray Cary Ware & Freidenrich LLP, Haile, Lisa A.	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	66 Drawing Figure(s); 61 Drawing Page(s)	
LINE COUNT:	19213	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods of obtaining vaccines by use of non-stochastic methods of directed evolution (DirectEvolution.TM.). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis.TM.) and non-stochastic polynucleotide reassembly (GeneReassembly.TM.). Through use of the claimed methods, vectors can be obtained which exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FILE 'HCAPLUS' ENTERED AT 16:01:56 ON 22 NOV 2005

L1	27	SEA FILE=REGISTRY ABB=ON PLU=ON GLYCOPHORIN A ?/CN
L2	12304	SEA FILE=HCAPLUS ABB=ON PLU=ON L1 OR BAEBL OR ERYTHROCYT? BIND? OR GLYCOPHORIN(W) (A OR B OR C OR E OR HA) OR (EBA175 OR EBA OR EBP) (S) ERYTHROCYT? OR GLYCOCONNECTIN OR GLYCO CONNECTIN OR SIALOGLYCOPROTEIN OR SIALO(W) (GLYCOPROTE IN OR GLYCO PROTEIN) OR SIALOGLYCO PROTEIN
L3	284	SEA FILE=HCAPLUS ABB=ON PLU=ON L2 AND (PLASMODIUM OR P) (W) FALCIPARUM
L8	1	SEA FILE=REGISTRY ABB=ON PLU=ON FORMAMIDE/CN
L9	23155	SEA FILE=HCAPLUS ABB=ON PLU=ON L8 OR FORMAMIDE OR FORMIMIDIC OR METHANAMIDE OR NSC 748 OR NSC748
L10	1	SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND L9

10/677980

L39 0 S L10 NOT L32

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, JAPIO' ENTERED AT 16:02:30 ON 22 NOV 2005)

L40 1 S L10

L41 0 S L40 NOT L35

(FILE 'HCAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, JAPIO, USPATFULL' ENTERED AT 16:05:40 ON 22 NOV 2005)

L42 4183 SEA ABB=ON PLU=ON "MAYER G"?/AU *-Author(s)*
L43 21778 SEA ABB=ON PLU=ON "MILLER L"?/AU
L44 5 SEA ABB=ON PLU=ON L42 AND L43
L45 25956 SEA ABB=ON PLU=ON L42 OR L43
L46 110 SEA ABB=ON PLU=ON L45 AND L3
L47 78 SEA ABB=ON PLU=ON L46 AND (PROTEIN OR POLYPROTEIN OR
POLYPEPTIDE OR PEPTIDE)

L50 14 S L47 AND (HYBRIDIS? OR HYBRIDIZ?)

L51 16 S L44 OR L50

L52 10 DUP REM L51 (6 DUPLICATES REMOVED)

L52 ANSWER 1 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2005:275167 USPATFULL

TITLE: **Plasmodium falciparum**
erythrocyte binding
protein baebl for use as a
vaccine

INVENTOR(S): **Mayer, Ghislaine**, Gaithersburg, MD,
UNITED STATES
Miller, Louis H., Rockville; MD, UNITED
STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239730	A1	20051027
APPLICATION INFO.:	US 2003-677980	A1	20031002 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2002-US10071, filed on 29 Mar 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-281130P	20010402 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1806	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention relates to Plasmodium falciparum Erythrocyte Binding Protein BAEBL for use as a vaccine.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L52 ANSWER 2 OF 10 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on

Searcher : Shears 571-272-2528

10/677980

STN

DUPLICATE 1

ACCESSION NUMBER: 2005:302211 BIOSIS
 DOCUMENT NUMBER: PREV200510096236
 TITLE: Characterization of the Plasmodium falciparum
 erythrocyte-binding ligand EBL-1.
 AUTHOR(S): **Mayer, G.** [Reprint Author]; **Miller, L.**
H.
 CORPORATE SOURCE: NIH, Lab Malaria and Vector Res, Bethesda, MD USA
 SOURCE: Molecular Biology of the Cell, (NOV 2004) Vol. 15, No.
 Suppl. S, pp. 464A-465A.
 Meeting Info.: 44th Annual Meeting of the
 American-Society-for-Cell-Biology. Washington, DC, USA.
 December 04 -08, 2004. Amer Soc Cell Biol.
 CODEN: MBCEEV. ISSN: 1059-1524.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 15 Aug 2005
 Last Updated on STN: 15 Aug 2005

L52 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2002:777627 HCAPLUS
 DOCUMENT NUMBER: 137:293522
 TITLE: **Plasmodium falciparum**
erythrocyte binding
protein BAEBL for use as vaccine
 against malarial Plasmodium parasite
 INVENTOR(S): **Mayer, Ghislaine; Miller, Louis**
H.
 PATENT ASSIGNEE(S): The Government of the United States of America,
 Represented by the Secretary, Department of Health
 and Human Services, USA
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078603	A2	20021010	WO 2002-US10071	20020329
WO 2002078603	A3	20030828		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005239730	A1	20051027	US 2003-677980	20031002
PRIORITY APPLN. INFO.:			US 2001-281130P	P 20010402
			WO 2002-US10071	A1 20020329

AB The invention relates to **Plasmodium falciparum**

Searcher : Shears 571-272-2528

Erythrocyte Binding Protein BAEBL
for use as a vaccine.

L52 ANSWER 4 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:301756 USPATFULL
TITLE: Binding domains from Plasmodium vivax and
Plasmodium falciparum erythrocyte
INVENTOR(S): Sim, Kim Lee, Gaithersburg, MD, UNITED STATES
Chitnis, Chetan, Washington, DC, UNITED STATES
Miller, Louis H., Bethesda, MD, UNITED STATES
Peterson, David S., Rockville, MD, UNITED STATES
Su, Xin-Zhuan, Rockville, MD, UNITED STATES
Wellems, Thomas E., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002169305	A1	20021114
	US 6962987	B2	20051108
APPLICATION INFO.:	US 2002-153273	A1	20020521 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-210288, filed on 11 Dec 1998, GRANTED, Pat. No. US 6392026 Division of Ser. No. US 1995-568459, filed on 7 Dec 1995, GRANTED, Pat. No. US 5849306 Continuation of Ser. No. US 1993-119677, filed on 10 Sep 1993, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	3119		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by Plasmodium falciparum or <i>P. vivax</i> . In particular, the polypeptides are derived from the binding domains of the proteins in the EBL family as well as the sialic acid binding protein (SABP) on <i>P. falciparum</i> merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on <i>P. vivax</i> merozoites.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L52 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:116395 USPATFULL
TITLE: Binding domains from plasmodium vivax and
plasmodium falciparum
erythrocyte binding
proteins
INVENTOR(S): Sim, Kim Lee, Gaithersburg, MD, United States
Chitnis, Chetan, Washington, DC, United States
Miller, Louis H., Bethesda, MD, United States
Peterson, David S., Rockville, MD, United States
Su, Xin-Zhuan, Rockville, MD, United States
Wellems, Thomas E., Rockville, MD, United States

PATENT ASSIGNEE(S): The United States of America as represented by the
Department of Health and Human Services,
Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6392026	B1	20020521
APPLICATION INFO.:	US 1998-210288		19981211 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-568459, filed on 7 Dec 1995, now patented, Pat. No. US 5849306		
	Continuation of Ser. No. US 1993-119677, filed on 10 Sep 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Navarro, Mark		
LEGAL REPRESENTATIVE:	Knobbe, Martens, Olson & Bear LLP		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	1227		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides isolated **polypeptides** useful in the treatment and prevention of malaria caused by **Plasmodium falciparum** or *P. vivax*. In particular, the **polypeptides** are derived from the binding domains of the **proteins** in the EBL family as well as the sialic acid binding **protein** (SABP) on *P. falciparum* merozoites. The **polypeptides** may also be derived from the Duffy antigen binding **protein** (DABP) on *P. vivax* merozoites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L52 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER: 1999:155211 USPATFULL

TITLE: Binding domains from plasmodium vivax and **plasmodium falciparum erythrocyte binding proteins**

INVENTOR(S): Sim, Kim Lee, Gaithersburg, MD, United States
Chitnis, Chetan, Washington, DC, United States
Miller, Louis H., Bethesda, MD, United States
Peterson, David S., Rockville, MD, United States
Su, Xin-Zhuan, Rockville, MD, United States
Wellems, Thomas E., Rockville, MD, United States

PATENT ASSIGNEE(S): The United States of America as represented by the
Secretary, Department of Health and Human Services,
Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5993827		19991130
APPLICATION INFO.:	US 1995-487826		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-119677, filed on 10 Sep 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cunningham, Thomas M.		

10/677980

LEGAL REPRESENTATIVE: Knobbe Martens Olson & Bear
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 4566

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides isolated **polypeptides** useful in the treatment and prevention of malaria caused by **Plasmodium falciparum** or *P. vivax*. In particular, the **polypeptides** are derived from the binding domains of the **proteins** in the DBL family as well as the sialic acid binding **protein** (SABP) on *P. falciparum* merozoites. The **polypeptides** may also be derived from the Duffy antigen binding **protein** (DABP) on *P. vivax* merozoites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L52 ANSWER 7 OF 10 USPATFULL on STN

ACCESSION NUMBER: 1998:156927 USPATFULL

TITLE: Binding domains from *Plasmodium vivax* and **Plasmodium falciparum** erythrocyte binding **proteins**

INVENTOR(S): Sim, Kim Lee, Gaithersburg, MD, United States
Chitnis, Chetan, Washington, DC, United States
Miller, Louis H., Bethesda, MD, United States

PATENT ASSIGNEE(S): Peterson, David S., Rockville, MD, United States
Su, Xin-Zhuan, Rockville, MD, United States
Wellems, Thomas E., Rockville, MD, United States
The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849306		19981215
APPLICATION INFO.:	US 1995-568459		19951207 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-119677, filed on 10 Sep 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cunningham, Thomas M.		
LEGAL REPRESENTATIVE:	Knobbe, Martens, Olson & Bear, LLP		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2490		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides isolated **polypeptides** useful in the treatment and prevention of malaria caused by **Plasmodium falciparum** or *P. vivax*. In particular, the **polypeptides** are derived from the binding domains of the **proteins** in the EBL family as well as the sialic acid binding **protein** (SABP) on *P. falciparum* merozoites. The **polypeptides** may also be derived from the Duffy antigen binding **protein** (DABP) on *P. vivax* merozoites.

Searcher : Shears 571-272-2528

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L52 ANSWER 8 OF 10 USPATFULL on STN
 ACCESSION NUMBER: 96:68110 USPATFULL
 TITLE: Plasmodium vivax and Plasmodium knowlesi Duffy receptor
 INVENTOR(S): **Miller, Louis H.**, Bethesda, MD, United States
 Adams, John H., Bethesda, MD, United States
 Kaslow, David C., Kensington, MD, United States
 Fang, Xiangdong, Bethesda, MD, United States
 PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5541292		19960730
APPLICATION INFO.:	US 1992-916408		19920721 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-554837, filed on 20 Jul 1990, now patented, Pat. No. US 5198347		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Draper, Garnette D.		
ASSISTANT EXAMINER:	Ulm, John D.		
LEGAL REPRESENTATIVE:	Townsend and Townsend Khourie and Crew		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	52 Drawing Figure(s); 30 Drawing Page(s)		
LINE COUNT:	1120		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to DNA segments encoding the Duffy receptor of a Plasmodium parasite, the recombinant DNA and to recombinantly produced Duffy receptor. The Duffy receptor can be utilized as a vaccine for humans against malaria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L52 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
 ACCESSION NUMBER: 1995:700782 HCAPLUS
 DOCUMENT NUMBER: 123:331352
 TITLE: Isolation of multiple sequences from the **Plasmodium falciparum** genome that encode conserved domains homologous to those in **erythrocyte-binding proteins**
 AUTHOR(S): Peterson, David S.; **Miller, Louis H.**; Wellems, Thomas E.
 CORPORATE SOURCE: Lab. Parasit. Dis., Natl. Inst. Allergy Infect. Dis., Bethesda, MD, 20892, USA
 SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1995), 92(15), 7100-4
 CODEN: PNASA6; ISSN: 0027-8424
 PUBLISHER: National Academy of Sciences
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Open reading frames in the **Plasmodium falciparum**

genome encode domains homologous to the adhesive domains of the ***P. falciparum* EBA-175 erythrocyte-binding protein** (eba-175 gene product) and those of the *Plasmodium vivax* and *Plasmodium knowlesi* Duffy antigen-binding **proteins**. These domains are referred to as Duffy binding-like (DBL), after the receptor that detects *P. vivax* invasion of Duffy blood group-positive human erythrocytes. Using oligonucleotide primers derived from short regions of conserved sequence, the authors have developed a reverse transcription-PCR method that amplifies sequences encoding the DBL domains of expressed genes. Products of these reverse transcription-PCR amplifications include sequences of single-copy genes (including eba-175) and variably transcribed genes that cross-hybridize to multiple regions of the genome. Restriction patterns of the multicopy genes show a high degree of polymorphism among different parasite lines, whereas single-copy genes are generally conserved. Characterization of the single-copy genes has identified a gene (eb1-1) that is related to eba-175 and is likely to be involved in **erythrocyte** invasion.

L52 ANSWER 10 OF 10 USPATFULL on STN

ACCESSION NUMBER: 93:24823 USPATFULL

TITLE: DNA encoding *Plasmodium vivax* and *Plasmodium knowlesi* Duffy receptor

INVENTOR(S): **Miller, Louis H.**, Bethesda, MD, United States

Adams, John H., Bethesda, MD, United States
Kaslow, David C., Kensington, MD, United States
Fang, Xiangdong, Bethesda, MD, United States

PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5198347		19930330
APPLICATION INFO.:	US 1990-554837		19900720 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lacey, David L.		
ASSISTANT EXAMINER:	Ulm, John D.		
LEGAL REPRESENTATIVE:	Cushman, Darby & Cushman		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	54 Drawing Figure(s); 30 Drawing Page(s)		
LINE COUNT:	1121		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to DNA segments encoding the Duffy receptor of a *Plasmodium* parasite, the recombinant DNA and to recombinantly produced Duffy receptor. The Duffy receptor can be utilized as a vaccine for humans against malaria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FILE 'HOME' ENTERED AT 16:15:31 ON 22 NOV 2005

10/677980

=> d his ful

(FILE 'HCAPLUS' ENTERED AT 15:21:59 ON 22 NOV 2005)
DEL HIS Y
D COST

FILE 'HCAPLUS' ENTERED AT 15:24:46 ON 22 NOV 2005

FILE 'REGISTRY' ENTERED AT 15:25:00 ON 22 NOV 2005
E GLYCOPHORIN A/CN 5

L1 27 SEA ABB=ON PLU=ON GLYCOPHORIN A ?/CN
E BAEBL/CN 5

FILE 'HCAPLUS' ENTERED AT 15:25:30 ON 22 NOV 2005

L2 12304 SEA ABB=ON PLU=ON L1 OR BAEBL OR ERYTHROCYT? BIND? OR
GLYCOPHORIN(W) (A OR B OR C OR E OR HA) OR (EBA175 OR EBA
OR EBP) (S) ERYTHROCYT? OR GLYCOCONNECTIN OR GLYCO CONNECTIN
OR SIALOGLYCOPROTEIN OR SIALO(W) (GLYCOPROTEIN OR GLYCO
PROTEIN) OR SIALOGLYCO PROTEIN

L3 284 SEA ABB=ON PLU=ON L2 AND (PLASMODIUM OR P) (W) FALCIPARUM
D KWIC

L4 89 SEA ABB=ON PLU=ON L3 AND (VACCIN? OR IMMUNIS? OR
IMMUNIZ?)

L5 249 SEA ABB=ON PLU=ON L2(L) ((PLASMODIUM OR P) (W) FALCIPARUM)

L6 57 SEA ABB=ON PLU=ON L5(L) (VACCIN? OR IMMUNIS? OR IMMUNIZ?)

D KWIC
L7 1 SEA ABB=ON PLU=ON L3 AND FORMAMIDE
D TI AU
D KWIC

FILE 'REGISTRY' ENTERED AT 15:32:08 ON 22 NOV 2005
E FORMAMIDE/CN 5

L8 1 SEA ABB=ON PLU=ON FORMAMIDE/CN
D CN

FILE 'HCAPLUS' ENTERED AT 15:32:40 ON 22 NOV 2005

L9 23155 SEA ABB=ON PLU=ON L8 OR FORMAMIDE OR FORMIMIDIC OR
METHANAMIDE OR NSC 748 OR NSC748

L10 1 SEA ABB=ON PLU=ON L3 AND L9

L11 3 SEA ABB=ON PLU=ON L3 AND (HYBRIDIS? OR HYBRIDIZ?)

L12 163 SEA ABB=ON PLU=ON L5(L) (POLYPEPTIDE OR POLYPROTEIN OR
PROTEIN OR PEPTIDE)

FILE 'REGISTRY' ENTERED AT 15:35:37 ON 22 NOV 2005

L13 8 SEA ABB=ON PLU=ON ("QS-21" OR "DETOX-PC" OR "MPL-SE" OR
"MOGM-CSF" OR "TITERMAX-G" OR "CRL-1005" OR GERBU OR
TERAMIDE OR PSC97B OR ADJUMER OR "PG-026" OR "GSK-1" OR
GCMF OR "B-ALETHINE" OR "MPC-026" OR ADJUVAX OR CPG ODN
OR BETAFFECTIN OR ALUM OR MF59)/CN

L14 11 SEA ABB=ON PLU=ON (QS 21 OR DETOX-PC OR MOGM CSF OR
TITERMAX G OR CRL 1005 OR PSC 97B OR ADJUMER OR PG 026 OR
GSK 1 OR B ALETHINE OR MPC 026 OR BETAFFECTIN OR ALUM OR MF
59)/CN

L15 1 SEA ABB=ON PLU=ON DETOX PC/CN
E MOGM/CN

L16 1 SEA ABB=ON PLU=ON GCMF/CN
E TITERMAX/CN 5

L17 2 SEA ABB=ON PLU=ON (TITERMAX/CN OR "TITERMAX GOLD"/CN)

Searcher : Shears 571-272-2528

10/677980

E "B-ALETHINE"/CN 5
E "B-ALETHINE"/CN 5
L18 1 SEA ABB=ON PLU=ON B-ALETHINE/CN
L19 19 SEA ABB=ON PLU=ON L13 OR L14 OR L15 OR L16 OR L17 OR L18

FILE 'HCAPLUS' ENTERED AT 15:43:38 ON 22 NOV 2005
L20 47043 SEA ABB=ON PLU=ON L19 OR QS21 OR QS 21 OR DETOX PC OR
MPL SE OR MOGM OR TITERMAX OR CRL 1005 OR GERBU OR
TERAMIDE OR PSC97B OR ADJUMER OR (PG OR MPC) (W) (026 OR 26)
OR GSK(W) (1 OR I) OR GCMAF OR (B OR BETA) (W) ALETHINE OR
ADJUVAX OR CPG ODN OR BETAPECTIN OR ALUM OR MF59 OR MF 59
L21 149 SEA ABB=ON PLU=ON L20 AND MILLER ?/AU
L22 1 SEA ABB=ON PLU=ON L21 AND MAYER ?/AU
D KWIC

FILE 'REGISTRY' ENTERED AT 15:46:11 ON 22 NOV 2005
L*** DEL 1 S PSC 97B
L23 1 SEA ABB=ON PLU=ON PSC 97B/CN
E GERBU/CN
L24 4 SEA ABB=ON PLU=ON GERBU ?/CN

FILE 'HCAPLUS' ENTERED AT 15:46:43 ON 22 NOV 2005
D QUE L20
L25 48047 SEA ABB=ON PLU=ON L20 OR L23 OR L24 OR PSC 97B
L26 152 SEA ABB=ON PLU=ON L25 AND MILLER ?/AU
L27 1 SEA ABB=ON PLU=ON L26 AND MAYER ?/AU
D KWIC

FILE 'REGISTRY' ENTERED AT 15:48:02 ON 22 NOV 2005
E "GM-CSF"/CN 5
L28 9 SEA ABB=ON PLU=ON "GM-CSF"?/CN

FILE 'HCAPLUS' ENTERED AT 15:48:15 ON 22 NOV 2005
L29 68994 SEA ABB=ON PLU=ON L20 OR L23 OR L24 OR PSC 97B OR L28 OR
GMCSF OR (GM OR GRANUL?) (1W) (CSF OR COLONY STIMUL?)
L30 4 SEA ABB=ON PLU=ON L3 AND L29
L31 1 SEA ABB=ON PLU=ON L30 AND MAYER ?/AU
D KWIC

FILE 'REGISTRY' ENTERED AT 15:50:06 ON 22 NOV 2005

FILE 'HCAPLUS' ENTERED AT 15:50:06 ON 22 NOV 2005
D QUE L7
D QUE L30
L32 4 SEA ABB=ON PLU=ON L7 OR L30
D 1-4 .BEVSTR

FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, JAPIO' ENTERED AT 15:50:30 ON 22 NOV 2005
L33 1 SEA ABB=ON PLU=ON L7
L34 10 SEA ABB=ON PLU=ON L30
L35 10 SEA ABB=ON PLU=ON L33 OR L34
L36 6 DUP REM L35 (4 DUPLICATES REMOVED)
D 1-6 IBIB ABS

FILE 'USPATFULL' ENTERED AT 15:58:53 ON 22 NOV 2005
L37 59 SEA ABB=ON PLU=ON L3 AND L29
L38 15 SEA ABB=ON PLU=ON L37 AND (L9 OR FORMAMIDE)

Searcher : Shears 571-272-2528

10/677980

D QUE
D QUE
D 1-15 IBIB ABS

FILE 'HCAPLUS' ENTERED AT 16:01:04 ON 22 NOV 2005

D QUE L10
L39 0 SEA ABB=ON PLU=ON L10 NOT L32

FILE 'HCAPLUS' ENTERED AT 16:01:56 ON 22 NOV 2005

D QUE L10

FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, JAPIO' ENTERED AT 16:02:30 ON 22 NOV 2005

L40 1 SEA ABB=ON PLU=ON L10
L41 0 SEA ABB=ON PLU=ON L40 NOT L35

FILE 'HCAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
JICST-EPLUS, JAPIO, USPATFULL' ENTERED AT 16:05:40 ON 22 NOV 2005

L42 4183 SEA ABB=ON PLU=ON "MAYER G"?/AU
L43 21778 SEA ABB=ON PLU=ON "MILLER L"?/AU
L44 5 SEA ABB=ON PLU=ON L42 AND L43
L45 25956 SEA ABB=ON PLU=ON L42 OR L43
L46 110 SEA ABB=ON PLU=ON L45 AND L3
L47 78 SEA ABB=ON PLU=ON L46 AND (PROTEIN OR POLYPROTEIN OR
POLYPEPTIDE OR PEPTIDE)
L48 80 SEA ABB=ON PLU=ON L44 OR L47
L49 31 DUP REM L48 (49 DUPLICATES REMOVED)
L50 14 SEA ABB=ON PLU=ON L47 AND (HYBRIDIS? OR HYBRIDIZ?)
L51 16 SEA ABB=ON PLU=ON L44 OR L50
L52 10 DUP REM L51 (6 DUPLICATES REMOVED)
D 1-10 IBIB ABS

FILE 'HOME' ENTERED AT 16:15:31 ON 22 NOV 2005

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Nov 2005 VOL 143 ISS 22
FILE LAST UPDATED: 21 Nov 2005 (20051121/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

Searcher : Shears 571-272-2528

10/677980

STRUCTURE FILE UPDATES: 21 NOV 2005 HIGHEST RN 868586-21-4
DICTIONARY FILE UPDATES: 21 NOV 2005 HIGHEST RN 868586-21-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMI
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE MEDLINE

FILE LAST UPDATED: 16 NOV 2005 (20051116/UP). FILE COVERS 1950 TO DA

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP
RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 16 November 2005 (20051116/ED)

FILE EMBASE

FILE COVERS 1974 TO 17 Nov 2005 (20051117/ED)

Searcher : Shears 571-272-2528

10/677980

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIDS

FILE LAST UPDATED: 22 NOV 2005 <20051122/UP>
MOST RECENT DERWENT UPDATE: 200575 <200575/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
PLEASE CHECK:
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code>
FOR DETAILS. <<<

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html <

FILE CONFSCI

FILE COVERS 1973 TO 25 May 2005 (20050525/ED)

FILE SCISEARCH

FILE COVERS 1974 TO 17 Nov 2005 (20051117/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE JICST-EPLUS

FILE COVERS 1985 TO 21 NOV 2005 (20051121/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED
TERM (/CT) THESAURUS RELOAD.

FILE JAPIO

FILE LAST UPDATED: 4 NOV 2005 <20051104/UP>
FILE COVERS APR 1973 TO JULY 28, 2005

<<< GRAPHIC IMAGES AVAILABLE >>>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html <

FILE USPATFULL

Searcher : Shears 571-272-2528

10/677980

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 22 Nov 2005 (20051122/PD)
FILE LAST UPDATED: 22 Nov 2005 (20051122/ED)
HIGHEST GRANTED PATENT NUMBER: US6968571
HIGHEST APPLICATION PUBLICATION NUMBER: US2005257307
CA INDEXING IS CURRENT THROUGH 22 Nov 2005 (20051122/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 22 Nov 2005 (20051122/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2005

>>> USPAT2 is now available. USPATFULL contains full text of the
>>> original, i.e., the earliest published granted patents or
>>> applications. USPAT2 contains full text of the latest US
>>> publications, starting in 2001, for the inventions covered in
>>> USPATFULL. A USPATFULL record contains not only the original
>>> published document but also a list of any subsequent
>>> publications. The publication number, patent kind code, and
>>> publication date for all the US publications for an invention
>>> are displayed in the PI (Patent Information) field of USPATFULL
>>> records and may be searched in standard search fields, e.g., /PN,
>>> /PK, etc.

>>> USPATFULL and USPAT2 can be accessed and searched together
>>> through the new cluster USPATALL. Type FILE USPATALL to
>>> enter this cluster.

>>> Use USPATALL when searching terms such as patent assignees,
>>> classifications, or claims, that may potentially change from
>>> the earliest to the latest publication.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE HOME

Patent US20020127241-A1

;; CURRENT FILING DATE: 2001-08-07
;; PRIOR APPLICATION NUMBER: US 60/223,525

;; PRIOR FILING DATE: 2000-08-07
;; NUMBER OF SEQ ID NOS: 17
;; SOFTWARE: PatentIn version 3.1

;; SEQ ID NO 14
;; LENGTH: 1143

;; TYPE: PRT
;; ORGANISM: Mammalian

US-09-924-154-14

Query Match 93.8%; Score 6081; DB 3; Length 1143;
Best Local Similarity 99.6%; Pred. No. 0;
Matches 1130; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY	1	MKGYNIIYFLIPLIPLYNVIRINESIIIGRTLYNRQDESSDISRVNSPELNNHKTNIYDS	60
Db	7	MKGYNIIYFLIPLIPLYNVIRINESIIIGRTLYNRQDESSDISRVNSPELNNHKTNIYDS	66
QY	61	DYEDVNNKGLINSFVENKSVKKKRSISFINNKTYSYDIIPPSYSYRNDKFNLSSENEEDNSG	120
Db	67	DYEDVNNKGLINSFVENKSVKKKRSISFINNKTYSYDIIPPSYSYRNDKFNLSSENEEDNSG	126
QY	121	NTNSNNPANTSEISIGKDNKOYTFIQKRTHLFACGIGKRSIKWICRENSEKIVCVDPDRK	180
Db	127	NTNSNNPANTSEISIGKDNKOYTFIQKRTHLFACGIGKRSIKWICRENSEKIVCVDPDRK	186
QY	181	IOLCVANFLNSLETWKEFKEIFLISVNTAEKLLYNKNEGKOPSPFCNELRNSPSPFRSS	240
Db	187	IOLCVANFLNSLETWKEFKEIFLISVNTAEKLLYNKNEGKOPSPFCNELRNSPSPFRSS	246
QY	241	FIGDDMDGQNTDRVKGYNINIKPSDYKKEKNVEKLNIIKKEWKKKALNNHMI VNHKG	300
Db	247	FIGDDMDGQNTDRVKGYNINIKPSDYKKEKNVEKLNIIKKEWKKKALNNHMI VNHKG	306
QY	301	NISKECAIIPAREPQINLWIKENNFLEKKEKRLFLNIKDKVENKKYBACPGGCLPCS	360
Db	307	NISKECAIIPAREPQINLWIKENNFLEKKEKRLFLNIKDKVENKKYBACPGGCLPCS	366
QY	361	SYTSPMKKSKTQMEVLTNLYKKKNSGVDRKNFLNDLFFKKNQNDLDDFFKNEKEYDDLCD	420
Db	367	SYTSPMKKSKTQMEVLTNLYKKKNSGVDRKNFLNDLFFKKNQNDLDDFFKNEKEYDDLCD	426
QY	421	CRYTATIIKSFPLNGPAKNDVDIASQINVNDLGRFGCNYKSNNEKSNWCTGTFTNKPFGTC	480
Db	427	CRYTATIIKSFPLNGPAKNDVDIASQINVNDLGRFGCNYKSNNEKSNWCTGTFTNKPFGTC	486
QY	481	EPFRQTLCLGRYLLHGHEDYKHEHLLGASITYEAQLLKYKKEKDNALCSIIQNSYA	540
Db	487	EPFRQTLCLGRYLLHGHEDYKHEHLLGASITYEAQLLKYKKEKDNALCSIIQNSYA	546
QY	541	DLADIIKGSDDIKDYGGKQMBENLNKVNKDKRNESSLKIFREKWDENKENVKMSAV	600
Db	547	DLADIIKGSDDIKDYGGKQMBENLNKVNKDKRNESSLKIFREKWDENKENVKMSAV	606
QY	601	LKNKETCKDYDKEOKIPOFLRWFKENGDDPCFKRKEKIYSFESFKVECKKCCDENTCKN	660
Db	607	LKNKETCKDYDKEOKIPOFLRWFKENGDDPCFKRKEKIYSFESFKVECKKCCDENTCKN	666
QY	661	KCSYKKNWIDLKKSSEYKQVDKYTKDKNNKMYDNIDDEVKNKEANVYLKESKECKOVNFD	720
Db	667	KCSYKKNWIDLKKSSEYKQVDKYTKDKNNKMYDNIDDEVKNKEANVYLKESKECKOVNFD	726
QY	721	DKIFNESPNYEYDMCKCKDEIKYLNBIKYPKTKHDIYDIDTFSDTFDGDGTPISINANINE	780
Db	727	DKIFNESPNYEYDMCKCKDEIKYLNBIKYPKTKHDIYDIDTFSDTFDGDGTPISINANINE	786
QY	781	QKSGKDTNNTGNSHSDSDSPVSHPEPSDAAINVEKLSGDESSSETRGLINDPSVTNNV	840
Db	787	QKSGKDTNNTGNSHSDSDSPVSHPEPSDAAINVEKLSGDESSSETRGLINDPSVTNNV	846
QY	841	EVHDAASNTGGSVNTSDITNGHSESSINRTTNAQDIKIGRSQNEQSDNQSNSHSSDNG	900

Tue Nov 22 15:12:20 2005

us-10-677

Db	847	EVDASNTQGSVNTSDITNGHSESLNRTTNAQDIKIGSGNEQSDNQENSHSDNSG	906
Qy	901	SLTIGQVPSQEDNTQNTYDSQNPFRDTPNALASLPDDKINEIEGPDSSRDSSENGRGTTS	960
Db	907	SLTIGQVPSQEDNTQNTYDSQNPFRDTPNALASLPDDKINEIEGPDSSRDSSENGRGTTS	966
Qy	961	NTHDVRRTNIVSERRVNSHDFIRNGMANNNAHQYITQIENNGIIRGQESAGNSVNYKD	1020
Db	967	NTHDVRRTNIVSERRVNSHDFIRNGMANNNAHQYITQIENNGIIRGQESAGNSVNYKD	1026
Qy	1021	NPKRNFSENDHKKNIOEYNSRDTKRVREELKLSKQKCNNEYSMEYCTYSDERNSSP	1080
Db	1027	NPKRNFSENDHKKNIOEYNSRDTKRVREELKLSKQKCNNEYSMEYCTYSDERNSSP	1086
Qy	1081	GPCSREERKLCQOISDYCLKYFNFYSIYNYCISEIKSPYKCFKSEGOSSI	1134
Db	1087	GPCSREERKLCQOISDYCLKYFNFYSIYNYCISEIKSPYKCFKSEGOSSM	1140